Clinical Trial Update: Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 clinical trial evaluating the combination of bortezomib and low-dose cytarabine in high-risk myelodysplastic syndromes has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Bortezomib (bortezomib)
• CYTARABINE (CYTARABINE)

Snippet

Sponsor: Groupe Francophone des Myelodysplasies | Conditions: Myelodysplastic Syndromes | Phase 1, Phase 2 | Status: COMPLETED